ANRO
Alto Neuroscience, Inc.
NYSE: ANRO · HEALTHCARE · BIOTECHNOLOGY
$23.33
+0.60% today
Updated 2026-10-28
Market cap
$895.50M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.31
Dividend yield
—
52W range
$10 – $37
Volume
0.6M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.0
Quality
B+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$38.88
+66.65%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.17 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-19.76M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-27.71M | $-36.30M | $-61.43M | $-63.24M | $-27.64M |
| EPS | — | — | — | — | $-2.31 |
| Free cash flow | $-21.13M | $-33.92M | $-49.50M | $-51.79M | $-19.76M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Alto Neuroscience, Inc. trades at $23.33. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.17, it sits in the distress.
Frequently asked questions
What is Alto Neuroscience, Inc.'s stock price?
Alto Neuroscience, Inc. (ANRO) trades at $23.33.
Is Alto Neuroscience, Inc. overvalued?
Alto Neuroscience, Inc. carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Alto Neuroscience, Inc. (ANRO)?
The 12-month analyst consensus target is $38.88, about 66.7% above the current $23.33. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Alto Neuroscience, Inc.'s Altman Z-Score is 1.17, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio—
ROE-38.42%
Beta1.34
50D MA$29.89
200D MA$23.96
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.6M
Performance
1 week+5.09%
1 month-12.23%
3 months-18.51%
YTD+31.07%
1 year+66.17%
3 years—
5 years—